Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» bispecific antibodies
bispecific antibodies
J&J Wins Full FDA Approval for Rybrevant, Chemo Combo in NSCLC
BioSpace
Mon, 03/4/24 - 11:48 am
JNJ
FDA
bispecific antibodies
Rybrevant
non-small cell lung cancer
AbbVie and Genmab report data from follicular lymphoma antibody trial
Clinical Trials Arena
Mon, 12/11/23 - 09:59 am
AbbVie
Genman
clinical trials
epcoritamab
bispecific antibodies
relapsed or refractory follicular lymphoma
Biotheus, BioNTech Partner on Oncology Bispecific Antibody
Contract Pharma
Mon, 11/6/23 - 07:25 pm
BioNTech
bispecific antibodies
Biotheus
Amgen’s T-Cell Engager Shows Phase II Promise in Tough to Treat Lung Cancer
BioSpace
Fri, 10/20/23 - 11:34 am
Amgen
bispecific antibodies
T-cell engager
tarlatamab
clinical trials
Roche drops oral eye disease drug after completing phase 2, pulls back from solid tumor bispecific
Fierce Biotech
Thu, 10/19/23 - 11:36 am
Roche
diabetic retinopathy
solid tumors
bispecific antibodies
Regeneron’s linvoseltamab shows early and durable response in pre-treated MM
Clinical Trials Arena
Fri, 09/29/23 - 11:38 am
Regeneron
clinical trials
bispecific antibodies
linvoseltamab
Janssen granted additional European Commission approval for bispecific antibody
Biopharma Reporter
Tue, 08/22/23 - 09:54 am
Janssen
JNJ
bispecific antibodies
Europe
relapsed or refractory multiple myeloma
Regeneron rethinks CD28 bispecific R&D plan after 2 patients die
Fierce Biotech
Thu, 08/3/23 - 10:17 am
Regeneron
prostate cancer
clinical trials
patient deaths
REGN5678
bispecific antibodies
Takeda adds another F-Star collab to constellation, this time for $1B in biobucks
Fierce Biotech
Wed, 07/5/23 - 07:06 pm
Takeda
F-star Therapeutics
bispecific antibodies
immuno-oncology
AbbVie, Genmab Bi-Specific Lymphoma Data Tee Up Potential Challenge to Roche Drug
BioSpace
Thu, 06/29/23 - 11:15 pm
AbbVie
Genmab
Roche
follicular lymphoma
bispecific antibodies
epcoritamab
Lunsumio
J&J quietly punts a pair of early-stage bispecifics for solid tumors
Endpoints
Thu, 01/26/23 - 10:45 am
JNJ
bispecific antibodies
solid tumors
FDA grants priority reviews for Pfizer's Prevnar 20 for kids and Roche lymphoma candidate
Endpoints
Sun, 01/8/23 - 09:59 pm
FDA
priority review
Pfizer
Prevnar 20
vaccines
Roche
bispecific antibodies
glofitamab
lymphoma
AbbVie's Roche-rivaling blood cancer bispecific gets FDA priority review, triggering Genmab payday
Fierce Biotech
Mon, 11/21/22 - 10:12 am
AbbVie
Genmab
FDA
Roche
epcoritamab
bispecific antibodies
relapsed or refractory large B-cell lymphoma
Roche's Vabysmo lands clinical counterpunch in ophthalmology brawl with Eylea
Fierce Pharma
Thu, 10/27/22 - 11:02 am
Roche
Genentech
Vabysmo
bispecific antibodies
Eylea
Buy now, pay later: Jazz hands over $50M for Zymeworks' phase 3 HER2-directed bispecific
Fierce Biotech
Wed, 10/19/22 - 10:42 am
Jazz Pharmaceuticals
Zymeworks
HER2 inhbitor
bispecific antibodies
Seagen, amid deal rumors, spends $50M on a dual-targeting cancer drug
BioPharma Dive
Mon, 09/26/22 - 11:20 pm
Seagen
Merck
Lava Therapeutics
bispecific antibodies
LAVA-1223
J&J bags first nod for multiple myeloma bispecific to complement its own CAR-T offering
Fierce Pharma
Thu, 08/25/22 - 07:43 pm
JNJ
Europe
bispecific antibodies
Multiple Myeloma
Tecvayli
teclistamab
Amgen takes BiTEs out of pipeline, dropping BCMA, PSMA assets in light of data and competition
Fierce Biotech
Fri, 08/5/22 - 10:42 am
Amgen
BCMA
PSMA
Multiple Myeloma
bispecific antibodies
Following bispecific deal with Pfizer, quiet California biotech raises $65M, heads to the clinic
Endpoints
Tue, 06/14/22 - 07:25 pm
Dren Bio
Pfizer
bispecific antibodies
ASCO22: J&J, Pfizer trade BCMA bispecific data in myeloma
Pharmaforum
Mon, 06/6/22 - 09:52 am
JNJ
Pfizer
ASCO 2022
bispecific antibodies
relapsed or refractory multiple myeloma
Pages
1
2
3
4
next ›
last »